LGNZZ — LIGAND PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 886163 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 51,722,000 | 43,625,000 | 17,368,000 | -13,345,000 | 1,532,105,000 | 115,077,000 | 534,783,000 |
| Sep 2025 | 115,461,000 | 107,364,000 | 54,931,000 | 117,273,000 | 1,476,772,000 | 139,376,000 | 526,601,000 |
| Jun 2025 | 47,627,000 | 39,369,000 | 8,444,000 | 4,847,000 | 948,604,000 | 67,669,000 | 120,075,000 |
| Mar 2025 | 45,333,000 | 37,076,000 | -36,216,000 | -42,451,000 | 905,435,000 | 47,989,000 | 109,901,000 |
Yahoo Snapshot (yfinance, live)
Total Revenue
$290,542,016
EBITDA
$133,011,000
Free Cash Flow
$139,748,880
Enterprise Value
—
Total Cash
$1,357,757,952
Total Debt
$1,131,453,056
Shares Out
—
Trailing EPS
—
Book Value
$48.57
ROE
22.0%
ROA
4.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 10y)
Revenues vs Net Income (last 10y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 268,087,000 | 41,002,000 | 124,453,000 | 1,560,637,000 | 543,425,000 | 1,017,212,000 | — |
| Dec 2024 | 167,133,000 | -22,606,000 | -4,032,000 | 941,774,000 | 111,335,000 | 830,439,000 | — |
| Dec 2023 | 131,314,000 | 11,942,000 | 52,154,000 | 787,216,000 | 86,303,000 | 700,913,000 | — |
| Dec 2022 | 196,245,000 | 3,037,000 | -33,361,000 | 762,668,000 | 165,183,000 | 597,485,000 | — |
| Dec 2021 | 277,133,000 | 78,895,000 | 57,138,000 | 1,297,590,000 | 476,431,000 | 821,159,000 | — |
| Dec 2020 | 186,419,000 | 25,845,000 | -2,985,000 | 1,362,285,000 | 652,760,000 | 709,525,000 | — |
| Dec 2019 | 120,282,000 | 807,076,000 | 629,302,000 | 1,494,915,000 | 727,683,000 | 767,232,000 | — |
| Dec 2018 | 251,453,000 | 163,727,000 | 143,321,000 | 1,260,803,000 | 699,889,000 | 560,914,000 | — |
| Dec 2017 | 141,102,000 | 68,076,000 | 12,556,000 | 671,021,000 | 252,374,000 | 399,788,000 | — |
| Dec 2016 | 108,973,000 | 43,885,000 | -1,636,000 | 601,585,000 | 230,732,000 | 341,290,000 | — |
TTM Snapshot
Revenues TTM
$274,476,000
NetIncome TTM
$153,559,000
OpCashFlow TTM
—
Assets (Latest)
$1,532,105,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.04T | $1169.60 | — |
| JNJ | JOHNSON & JOHNSON | $618.09B | $256.48 | — |
| ABBV | AbbVie Inc. | $481.40B | $272.42 | — |
| MRK | Merck & Co., Inc. | $351.28B | $142.38 | — |
| NVS | NOVARTIS AG | $272.01B | $143.11 | — |
News headlines (Yahoo Finance, 1h cache)
Is Ligand Pharmaceuticals (LGND) Below Fair Value As It Funds AvenCell?
2026-09-29 16:04 · Yahoo
Ligand Pharmaceuticals (LGND) Stock May Be 27% Undervalued After A New Royalty Deal
2026-09-29 10:05 · Yahoo
Is Ligand Pharmaceuticals (LGND) Using AvenCell CAR-T Royalties To Redefine Its Cash-Flow Playbook?
2026-09-29 04:25 · Yahoo
Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones
2026-09-27 13:08 · Yahoo
Twilio downgraded, Synopsys upgraded: Wall Street's top analyst calls
2026-09-25 13:43 · Yahoo
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
2026-09-24 11:00 · Yahoo
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
2026-09-22 13:02 · Yahoo
Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
2026-09-22 13:00 · Yahoo
Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
2026-09-22 11:00 · Yahoo
Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book
2026-09-04 10:44 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.